002030.SHE Da An Gene Co Ltd of Sun Yat-Sen University
- Market cap
- CNY 7.49B
- P/E
- -
- P/B
- 1.04x
- ROE
- -2.7%
- Dividend yield
- 0.11%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002030.SHE undervalued?
Graham numberThe Graham number of Da An Gene Co Ltd of Sun Yat-Sen University cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Da An Gene Co Ltd of Sun Yat-Sen University fundamental analysis
No fundamental analysis for Da An Gene Co Ltd of Sun Yat-Sen University yet.
Da An Gene Co Ltd of Sun Yat-Sen University stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Da An Gene Co Ltd of Sun Yat-Sen University
Daan Gene Co., Ltd., together with its subsidiaries, researches and develops, manufactures, and sells clinical test reagents, instruments, and supporting consumables in China. It operates through two segments, Biological Products and Related Business and Financial Business. The company offers PCR testing kits, including hepatitis virus, human papillomavirus (HPV), sexually transmitted infections sexually transmitted infections, human immunodeficiency virus, blood screening, …
Full company profileDa An Gene Co Ltd of Sun Yat-Sen University financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Da An Gene Co Ltd of Sun Yat-Sen University annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.61B | 1.54B | 1.48B | 1.10B | 5.34B | 7.66B | 12.0B | 1.18B | 853M | 758M | 696M |
| Gross Profit | 696M | 658M | 611M | 542M | 3.74B | 5.70B | 8.43B | 380M | 223M | 245M | 261M |
| Operating Income | 102M | 111M | 103M | 6.19M | 2.94B | 4.13B | 6.33B | 122M | -1.07B | -297M | -176M |
| EBITDA | 186M | 158M | 167M | -7.83M | 2.62B | 4.09B | 6.35B | -11.8M | -374M | -453M | -192M |
| Net Income | 107M | 86.4M | 102M | 92.2M | 2.45B | 3.62B | 5.41B | 105M | -925M | -744M | -187M |
| EPS | 0.08 | 0.06 | 0.07 | 0.07 | 1.75 | 2.58 | 3.86 | 0.07 | -0.66 | -0.53 | -0.13 |
| Balance Sheet | |||||||||||
| Total Assets | 4.14B | 4.64B | 3.66B | 3.56B | 6.70B | 10.3B | 14.8B | 11.0B | 9.58B | 8.51B | 8.25B |
| Total Liabilities | 1.59B | 2.00B | 1.46B | 1.47B | 2.19B | 2.68B | 3.14B | 1.86B | 1.43B | 1.15B | 1.03B |
| Shareholders' Equity | 1.61B | 1.68B | 1.82B | 1.84B | 4.27B | 7.35B | 11.3B | 8.88B | 7.88B | 7.14B | 7.00B |
| Cash & Short-term Investments | 1.46B | 1.26B | 386M | 267M | 1.76B | 2.56B | 3.08B | 2.40B | 935M | 506M | 814M |
| Total Debt | 1.17B | 1.26B | 1.03B | 1.01B | 387M | 371M | 225M | 353M | 157M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -381M | -220M | 392M | 93.0M | 2.51B | 3.30B | 4.15B | 846M | 300M | 319M | - |
| Capital Expenditure | 221M | 191M | 100M | 93.3M | 365M | 659M | 1.50B | 573M | 174M | 239M | 57.0M |
| Free Cash Flow | -602M | -411M | 292M | -354K | 2.15B | 2.65B | 2.65B | 207M | 126M | 80.5M | 92.3M |
| Ratios | |||||||||||
| ROE | 6.6% | 5.1% | 5.6% | 5.0% | 57.4% | 49.2% | 47.9% | 1.2% | -11.7% | -10.4% | -2.7% |
| ROA | 2.6% | 1.9% | 2.8% | 2.6% | 36.6% | 35.0% | 36.7% | 0.9% | -9.7% | -8.7% | -2.3% |
| Net Profit Margin | 6.6% | 5.6% | 6.9% | 8.4% | 45.9% | 47.2% | 44.9% | 8.9% | -108.5% | -98.2% | -26.8% |
| Debt to Equity | 0.72x | 0.75x | 0.57x | 0.55x | 0.09x | 0.05x | 0.02x | 0.04x | 0.02x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Da An Gene Co Ltd of Sun Yat-Sen University dividends
- Dividend yield
- 0.11%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 14, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 8.46M | 0.01 | - |
| 2024 | CNY 27.9M | 0.02 | - |
| 2023 | CNY 2.46B | 1.75 | 2,346.7% |
| 2022 | CNY 1.56B | 1.11 | 28.8% |
| 2021 | CNY 482M | 0.34 | 13.3% |
| 2020 | CNY 19.9M | 0.01 | 0.8% |
| 2019 | CNY 32.7M | 0.02 | 35.5% |
| 2018 | CNY 103M | 0.07 | 101.4% |
| 2017 | CNY 95.8M | 0.07 | 110.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.6:1 on May 19, 2021.
Who owns Da An Gene Co Ltd of Sun Yat-Sen University
- Insiders 35.45%
- Institutions 1.47%
- Public & others 63.08%
- Shares outstanding 1.40B
- Free float 1.01B
Da An Gene Co Ltd of Sun Yat-Sen University company profile
- Company name
- Da An Gene Co Ltd of Sun Yat-Sen University
- Ticker
- 002030.SHE
- ISIN
- CNE000001KP1
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Jul 23, 2004
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,506
- Fiscal year end
- December
- Address
- No.19, Xiangshan Road, Guangzhou, China, 510665
- Phone
- 86 20 3229 0789
- Website
- daangene.com
About Da An Gene Co Ltd of Sun Yat-Sen University
Daan Gene Co., Ltd., together with its subsidiaries, researches and develops, manufactures, and sells clinical test reagents, instruments, and supporting consumables in China. It operates through two segments, Biological Products and Related Business and Financial Business. The company offers PCR testing kits, including hepatitis virus, human papillomavirus (HPV), sexually transmitted infections sexually transmitted infections, human immunodeficiency virus, blood screening, respiratory infections, digestive pathogens, public health, coronavirus disease (COVID-19), tumor marker, pharmacogenomics, nucleic acid extraction, and viral transport medium (VTM) collection kits. It also provides molecular diagnostic instruments comprising PCR detection systems, nucleic acid extraction systems, and sample transfer processing systems. In addition, the company offers immunoassay test kits that include COVID-19 rapid test kits; pathology tests, such as liquid based cytology production and automatic sample transfer machines; and auto biochemistry analyzers. It sells its products under the Daan Gene, Darui Biology, LBP, and Zhongshan Bio-Tech brands. The company was formerly known as Da An Gene Co., Ltd. of Sun Yat-Sen University. Daan Gene Co., Ltd. was incorporated in 1988 and is headquartered in Guangzhou, China.
Da An Gene Co Ltd of Sun Yat-Sen University management
5- Mr. Chen Hong weiGM & Vice Chairman · born 1974
- Mr. Huang ZhizhengDeputy GM, CFO & Director · born 1979
- Mr. Yang WangDeputy GM & Marketing Director · born 1986
- Mr. Zhang Wei JieDeputy GM & Director · born 1971
- Mr. Liang Zhi kunDeputy GM & Director · born 1985